Anti-amyloid immunotherapies in Alzheimer's disease (AD) are newly authorized for use in the European Union (AD). In a national online survey in 2024, we aimed to assess French practitioners’ opinion and knowledge regarding indications and risk management plan. Answers were based on clinical trial criteria. On 303 practitioners, most knew general indications except 19.1% who considered prescribing without AD biomarkers. Side effects were correctly identified, but specific knowledge on amyloid-related imaging abnormalities was lacking. Tertiary memory clinic practitioners had better knowledge on indications (p < 0.001) and side effects (p = 0.033).
HardyJAHigginsGA. Alzheimer’s disease: the amyloid cascade hypothesis. Science1992; 256: 184–185.
4.
JackCRKnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol2010; 9: 119–128.
5.
KeppKPRobakisNKHøilund-CarlsenPF, et al.The amyloid cascade hypothesis: an updated critical review. Brain2023; 146: 3969–3990.
6.
Van DyckCHSwansonCJAisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med2023; 388: 9–21.
7.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
8.
BarakosJPurcellDSuhyJ, et al.Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis2022; 9: 211–220.
BurkeJFKerberKALangaKM, et al.Lecanemab. Neurology2023; 101: 661–665.
11.
SatoKNiimiYIharaR, et al.Real-world lecanemab adoption in Japan 1 year after launch: insights from 311 specialists on infrastructure and reimbursement barriers. Alzheimers Dement2025; 21: e70652.
12.
MichaelianJCRoweCCKurrleSE, et al.Is Australia ready for the rollout of amyloid-targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics. Intern Med J2025; 55: 1081–1089.
13.
BlackSEBuddNNygaardHB, et al.A model predicting healthcare capacity gaps for Alzheimer's disease-modifying treatment in Canada. Can J Neurol Sci2024; 51: 487–494.
14.
PimouguetCBassiVSommeD, et al.The 2008–2012 French Alzheimer plan: a unique opportunity for improving integrated care for dementia. J Alzheimers Dis2013; 34: 307–314.
15.
SpinneyL. Alzheimer’s disease funding and the French health system. Lancet Neurol2008; 7: 26–27.
16.
VillainNPlancheVLilamandM, et al.Lecanemab for early Alzheimer’s disease: appropriate use recommendations from the French federation of memory clinics. J Prev Alzheimers Dis2025; 12: 100094.
17.
PaquetCLatourFSaulnierI, et al.[Multicenter study on lumbar puncture indication, clinical practice and feasibility]. Rev Neurol (Paris)2012; 168: 28–32.
18.
Mouton-LigerFWallonDTroussièreA-C, et al.Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric study. J Neurol2014; 261: 144–151.
19.
VrillonAGonzales-MarabalLPaquetC, et al.Developing an immersive 3D video for lumbar puncture teaching. Med Educ2022; 56: 579–580.
20.
LilamandMCognatEGoutagnyS, et al.[Biomarkers of Alzheimer’s disease in older and oldest old patients]. Geriatr Psychol Neuropsychiatr Vieil2019; 17: 65–72.
21.
VrillonAGonzales-MarabalLCeccaldiP-F, et al.Using virtual reality in lumbar puncture training improves students learning experience. BMC Med Educ2022; 22: 244.
22.
RabinoviciGDKnopmanDSArbizuJ, et al.Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. J Nucl Med2025; 66: S5–S31.
23.
DuboisBVillainNSchneiderL, et al.Alzheimer disease as a clinical-biological construct—an international working group recommendation. JAMA Neurol2024; 81: 1304.
24.
JackCRBarrioJRKepeV. Cerebral amyloid PET imaging in Alzheimer’s disease. Acta Neuropathol2013; 126: 643–657.
25.
KepeVMoghbelMCLångströmB, et al.Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis2013; 36: 613–631.
26.
InagawaYKamiyaTMiyagiY, et al.Evaluation of the effects of lecanemab treatment on brain atrophy using voxel-based specific regional analysis system for Alzheimer’s disease. J Alzheimers Dis2026; 110: 1225–1234.
27.
AlvesFKalinowskiPAytonS. Accelerated brain volume loss caused by anti-β-amyloid drugs: a systematic review and meta-analysis. Neurology2023; 100: e2114–e2124.
28.
BelderCRSBocheDNicollJAR, et al.Brain volume change following anti-amyloid β immunotherapy for Alzheimer’s disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol2024; 23: 1025–1034.
29.
PaquetCNicollJALoveS, et al.Downregulated apoptosis and autophagy after anti-Aβ immunotherapy in Alzheimer’s disease. Brain Pathol2018; 28: 603–610.
30.
PaquetCAminJMouton-LigerF, et al.Effect of active Aβ immunotherapy on neurons in human Alzheimer’s disease. J Pathol2015; 235: 721–730.
31.
Serrano-PozoAWilliamCMFerrerI, et al.Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain2010; 133: 1312–1327.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
